Showing results (71-80 of 217) with videos related to
Sort By:
Pageof 22
The Oncologist|April 25, 2019
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint InhibitorsAlberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso, et al.Advances in Biochemical Engineering/Biotechnology|September 20, 2012
MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic PotentialNaomi D'souza, Jorge Sans Burns, Giulia Grisendi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancerAlfredo Falcone, Gianluca Masi, Giacomo Allegrini, et al.The Oncologist|July 25, 2008
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient managementValentina Guarneri, Simona Giovannelli, Guido Ficarra, et al.The Oncologist|August 19, 2018
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor BiologyGaia Griguolo, Stephane Pouderoux, Maria Vittoria Dieci, et al.Cytokine|June 21, 2021
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratificationLoredana Urso, Micol Silic-Benussi, Alice Boscolo, et al.Cancer Chemotherapy and Pharmacology|June 19, 2014
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariatesDan Lu, Sandhya Girish, Yuying Gao, et al.Cancer Genetics and Cytogenetics|June 2, 2010
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignanciesGiovanni Ponti, Gabriele Luppi, Francesca Giacobbi, et al.Cancer|May 21, 2011
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancerPatricia K Corey-Lisle, Ronald Peck, Pralay Mukhopadhyay, et al.International Journal of Cancer|March 27, 2023
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trialElżbieta Senkus, Suzette Delaloge, Susan M Domchek, et al.Pageof 22